Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
DNA/RNA Damage Antibody
DNA/RNA Damage Antibody, Clone 15A3
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC, ICC, E, DB |
|---|---|
| Host | Mouse |
| Isotype | IgG2b |
| Clonality | Monoclonal |
| Description | Mouse Anti- DNA/RNA Damage Monoclonal IgG2b |
| Target/Specificity | Recognizes markers of oxidative damage to DNA (8-hydroxy-2’-deoxyguanosine, 8-hydroxyguanine and 8-hydroxyguanosine). |
| Other Names | 8-Hydroxy Guanine Antibody, 8-OH-dG Antibody, 8OHG Antibody, 80G Antibody, 8 hydroxyguanine Antibody, 8 hydroxy 2’ deoxyguanosine Antibody, 8 hydroxyguanosine Antibody, 8 OHG Antibody, 8-OHG Antibody, 8OHdG Antibody |
| Trademark | MOLECULAR SIGNATURE® |
| Clone Names | 15A3 |
| Immunogen | 8-hydroxy-guanosine-BSA and –casein conjugates |
| Purification | Protein G Purified |
| Storage | -20ºC |
| Storage Buffer | PBS, 50% glycerol, 0.09% sodium azide |
| Shipping Temperature | Blue Ice or 4ºC |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
DNA or RNA damage is due to environmental factors and normal metabolic processes inside the cell, that then hinder the ability of the cell to carry out its functions. There are four main types of DNA due to endogenous cellular processes and they are oxidation, alkylation, hydrolysis and mismatch of the bases. During the oxidation of bases, highly reactive chemical entities collectively known as RONS, occurs. RONS stands for reactive oxygen and nitrogen species and includes nitric oxide, superoxide, hydroxyl radical, hydrogen peroxide and peroxynitrite. Numerous studies have shown that RONS causes a variety of issues including DNA damage(1). 8-hydroxyguanine, 8-hydroxy-2’-deoxyguanonsine and 8- hydroxyguanosine are all RNA and DNA markers of oxidative damage. 8-hydroxy-2’-guanosine is produced by reactive oxygen and nitrogen species including hydroxyl radical and peroxynitrite. Specifically its high biological relevance is due to its ability to induce G to T transversions, which is one of the most frequent somatic mutations (2). 8-hydroxy-guanine has been the most frequently studied type of DNA base damage, with studies in diabetes, and cancer. Base modifications of this type arise from radical-induced hydroxylation and cleavage reactions of the purine ring (3, 4). And finally, 8-hydroxy-guanosine, like 8-hydroxy-2’-guanosine, induces a mutagenic transversion of G to T in DNA. Its role has specifically been tested in the development of diabetes, hypertension and strokes (5, 6, and 7).
References
1. Kim H.W., Murakami A., Williams M.V., and Ohigashi H. (2003) Carcinogenesis 24(2): 235-241.
2. Pilger A. and Rudiger H.W. (2006) Int Arch Occup Environ Health. 80(1): 1-15.
3. Malins D.C. and Haimanot R. (1991) Cancer Res. 51(19): 5430-5432.
4. Kvam E. and Tyrrell R.M. (1997) Carcinogenesis 18(11): 2281-2283.
5. Kowluru R.A., Atasi L., and Ho Y.S. (2006) Invest Ophthalmol Vis Sci 47(4): 1594-9.
6. Bowers R. et al. (2004) Am J Respir Crit Care Med. 169(6): 764-9.
7. Cui J., Holmes E.H., Greene T.G., and Liu P.K. (2000) Faseb J. 14(7): 955-67.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
